We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $2.49 billion. The consensus mark for earnings is pinned at $1.84 per share.
Let's see how things might have shaped up for Zoetis in the soon-to-be-reported quarter.
Factors to Consider Regarding ZTS’ Q2 Earnings
Zoetis derives the majority of its revenues from a diversified product portfolio of medicines and vaccines used to treat and protect livestock and companion animals. The company reports business results under two geographical operating segments — the United States and International.
First-quarter revenues in the U.S. segment are likely to have decreased from the year-ago quarter, primarily due to lower sales of Zoetis’ companion animal products and an increasingly competitive landscape. The Zacks Consensus Estimate for revenues generated from this segment is pegged at $1.33 billion.
Revenues from the International segment are expected to have increased in the to-be-reported quarter due to higher sales of companion animal and livestock products. The Zacks Consensus Estimate for revenues generated from this segment is pegged at $1.14 billion.
Year to date, Zoetis shares have plunged 38.6% compared with the industry’s 4.5% decline.
Image Source: Zacks Investment Research
Companion animal products sales, particularly ZTS’ parasiticides portfolio, including Simparica and ProHeart franchises, and its key dermatology products, including Apoquel and Cytopoint, are expected to have driven revenues in both the U.S. and International segments in the to-be-reported quarter.
However, Zoetis’ monoclonal antibody products for osteoarthritis pain, Librela for dogs and Solensia for cats, are expected to have posted a decline in sales in the U.S. segment due to fears of side effects in some dogs.
Apoquel is also approved as the first and only chewable treatment in the United States for controlling pruritus related to allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. The drug’s expanded label is likely to have boosted sales in the first quarter.
In 2025, the FDA approved a new indication for Zoetis’ Simparica Trio to prevent flea tapeworm infections by targeting and killing vector fleas in treated dogs. With this approval, the triple combo drug is now the only canine combination parasiticide indicated to prevent flea tapeworm infections at the source by eliminating carrier fleas before they can transmit the parasite. The label expansion is expected to have driven sales in the to-be-reported quarter.
Zoetis' livestock product sales are expected to have increased in the second quarter, supported by continued broad-based strength across its core species portfolio. In the United States, growth is likely to have been driven by cattle, poultry and swine products, while the International segment is expected to have benefited from broad-based demand across cattle, swine, poultry and fish.
ZTS Earnings Surprise History
Zoetis has a mixed earnings surprise history so far. The bottom line surpassed estimates in three of the trailing four quarters and missed on the remaining occasion, delivering an average surprise of 3.58%. In the last reported quarter, the company delivered a negative surprise of 4.97%.
Earnings Whispers for ZTS
Our proven model does not predict an earnings beat for Zoetis this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat, which is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: ZTS has an Earnings ESP of -0.75%.
Zacks Rank: Zoetis currently carries a Zacks Rank #4 (Sell).
Here are some stocks worth considering from the healthcare space, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
Shares of HRMY have lost 5.9% year to date. The company’s earnings missed estimates in each of the trailing four quarters, delivering an average negative surprise of 25.16%. Harmony is scheduled to report second-quarter results on Aug. 4, before the opening bell.
ACADIA Pharmaceuticals (ACAD - Free Report) has an Earnings ESP of +25.00% and a Zacks Rank #2 at present.
Shares of ACAD have lost 3.1% year to date. The company’s earnings beat estimates in three of the trailing four quarters and missed on the remaining occasion, delivering an average surprise of 20.83%. Acadia is scheduled to report second-quarter results on Aug. 4.
CRISPR Therapeutics (CRSP - Free Report) has an Earnings ESP of +1.94% and a Zacks Rank #3 at present.
Shares of CRSP have lost 8.4% year to date. CRISPR’s earnings beat estimates in two of the trailing four quarters and missed on the remaining two occasions, delivering an average negative surprise of 1.95%.
View the Zacks #1 Rank List
Image: Shutterstock
ZTS Set to Report Q2 Earnings: Here's What Investors Should Expect
Key Takeaways
Zoetis, Inc. (ZTS - Free Report) is slated to report second-quarter results on Aug. 6, 2026, before the opening bell.
The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $2.49 billion. The consensus mark for earnings is pinned at $1.84 per share.
Let's see how things might have shaped up for Zoetis in the soon-to-be-reported quarter.
Factors to Consider Regarding ZTS’ Q2 Earnings
Zoetis derives the majority of its revenues from a diversified product portfolio of medicines and vaccines used to treat and protect livestock and companion animals. The company reports business results under two geographical operating segments — the United States and International.
First-quarter revenues in the U.S. segment are likely to have decreased from the year-ago quarter, primarily due to lower sales of Zoetis’ companion animal products and an increasingly competitive landscape. The Zacks Consensus Estimate for revenues generated from this segment is pegged at $1.33 billion.
Revenues from the International segment are expected to have increased in the to-be-reported quarter due to higher sales of companion animal and livestock products. The Zacks Consensus Estimate for revenues generated from this segment is pegged at $1.14 billion.
Year to date, Zoetis shares have plunged 38.6% compared with the industry’s 4.5% decline.
Image Source: Zacks Investment Research
Companion animal products sales, particularly ZTS’ parasiticides portfolio, including Simparica and ProHeart franchises, and its key dermatology products, including Apoquel and Cytopoint, are expected to have driven revenues in both the U.S. and International segments in the to-be-reported quarter.
However, Zoetis’ monoclonal antibody products for osteoarthritis pain, Librela for dogs and Solensia for cats, are expected to have posted a decline in sales in the U.S. segment due to fears of side effects in some dogs.
Apoquel is also approved as the first and only chewable treatment in the United States for controlling pruritus related to allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. The drug’s expanded label is likely to have boosted sales in the first quarter.
In 2025, the FDA approved a new indication for Zoetis’ Simparica Trio to prevent flea tapeworm infections by targeting and killing vector fleas in treated dogs. With this approval, the triple combo drug is now the only canine combination parasiticide indicated to prevent flea tapeworm infections at the source by eliminating carrier fleas before they can transmit the parasite. The label expansion is expected to have driven sales in the to-be-reported quarter.
Zoetis' livestock product sales are expected to have increased in the second quarter, supported by continued broad-based strength across its core species portfolio. In the United States, growth is likely to have been driven by cattle, poultry and swine products, while the International segment is expected to have benefited from broad-based demand across cattle, swine, poultry and fish.
ZTS Earnings Surprise History
Zoetis has a mixed earnings surprise history so far. The bottom line surpassed estimates in three of the trailing four quarters and missed on the remaining occasion, delivering an average surprise of 3.58%. In the last reported quarter, the company delivered a negative surprise of 4.97%.
Earnings Whispers for ZTS
Our proven model does not predict an earnings beat for Zoetis this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat, which is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: ZTS has an Earnings ESP of -0.75%.
Zacks Rank: Zoetis currently carries a Zacks Rank #4 (Sell).
Zoetis Inc. Price, Consensus and EPS Surprise
Zoetis Inc. price-consensus-eps-surprise-chart | Zoetis Inc. Quote
Stocks to Consider
Here are some stocks worth considering from the healthcare space, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
Harmony Biosciences (HRMY - Free Report) has an Earnings ESP of +14.14% and sports a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Shares of HRMY have lost 5.9% year to date. The company’s earnings missed estimates in each of the trailing four quarters, delivering an average negative surprise of 25.16%. Harmony is scheduled to report second-quarter results on Aug. 4, before the opening bell.
ACADIA Pharmaceuticals (ACAD - Free Report) has an Earnings ESP of +25.00% and a Zacks Rank #2 at present.
Shares of ACAD have lost 3.1% year to date. The company’s earnings beat estimates in three of the trailing four quarters and missed on the remaining occasion, delivering an average surprise of 20.83%. Acadia is scheduled to report second-quarter results on Aug. 4.
CRISPR Therapeutics (CRSP - Free Report) has an Earnings ESP of +1.94% and a Zacks Rank #3 at present.
Shares of CRSP have lost 8.4% year to date. CRISPR’s earnings beat estimates in two of the trailing four quarters and missed on the remaining two occasions, delivering an average negative surprise of 1.95%.